Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.48 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Theofibrate SCHEMBL3960649 | 1.00 | ADORA2B (0.60) | ADORA2BLMNAMAPK1RXFP1ALDH1A1 | |
| Theofibrate SCHEMBL28085094 | 0.89 | LMNA (0.51) | ADORA2BLMNAMAPK1RXFP1ALDH1A1 | |
| SCHEMBL10963461 | 0.86 | LMNA (0.58) | ADORA2BLMNAMAPK1RXFP1ALDH1A1 | |
| SCHEMBL11460190 | 0.86 | OPRK1 (0.55) | ADORA2BLMNAMAPK1RXFP1ALDH1A1 | |
| SCHEMBL11883059 | 0.84 | LMNA (0.52) | ADORA2BLMNAMAPK1RXFP1ALDH1A1 | |
| Acefylline Clofibrol SCHEMBL2110473 | 0.80 | MAPK1 (0.61) | ADORA2BLMNAMAPK1RXFP1MAPT | |
| SCHEMBL28025751 | 0.76 | ADORA2B (1.00) | ADORA2BLMNAMAPK1RXFP1MAPT | |
| SCHEMBL11823628 | 0.74 | LMNA (0.55) | ADORA2BLMNAMAPK1RXFP1MAPT | |
| Xanthinol SCHEMBL29388798 | 0.73 | LMNA (0.61) | ADORA2BLMNAMAPK1RXFP1ALDH1A1 | |
| SCHEMBL11823621 | 0.73 | LMNA (0.48) | ADORA2BLMNAMAPK1RXFP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2395 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| US-20250367216-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250367217-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | claimed |
| CN-113939288-B | Modulators of MAS-related G protein receptor X4 and related products and methods | 伊赛恩特制药公司 | 2025-04-25 | — | — | CN | claimed |
| CN-116270724-B | Polysaccharide selenium nanoparticle and preparation method and application thereof | 青岛农业大学 | 2024-10-25 | — | — | CN | claimed |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-09-12 | — | — | US | claimed |
| CN-118236501-A | A composition containing PPARα agonist and folic acid substances | 深圳奥萨医药有限公司 | 2024-06-25 | — | — | CN | claimed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | claimed |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-05-25 | — | — | US | claimed |
| US-11643399-B2 | Modulators of mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-05-09 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| US-6133293-A | INSULIN SENSITIVITY ENHANCER IN COMBINATION WITH OTHER ANTIDIABETICS DIFFERING FROM THE ENHANCER IN THE MECHANISM OF ACTION; POTENT DEPRESSIVE EFFECT ON DIABETIC HYPERGLYCEMIA; 2,4-THIAZOLIDINEDIONES AND OXAZOLIDINEDIONES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-17 | — | — | US | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2000021504-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2000-04-20 | — | — | WO | claimed |
| EP-0935523-A4 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GEN MILLS INC (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0935523-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GENERAL MILLS, INC. (US) | 1999-08-18 | — | — | EP | claimed |
| CN-1215322-A | Method for encapsulating caplets in capsules and solid dosage forms obtainable by this method | WARNER LAMBERT CO (US) | 1999-04-28 | — | — | CN | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| CN-1170346-A | Process for encapsulation of caplets in capsule and solid dasage forms obtainable by such process | WARNER LAMBERT CO (US) | 1998-01-14 | — | — | CN | claimed |
| US-4246264-A | Treatment of hyperuricaemia with etofylline clofibrate | LUDWIG MERCKLE, K.G., CHEM. PHARM. FABRIK (DE) | 1981-01-20 | — | — | US | claimed |